Panos G Christakis1, Elvira Agrón2, Michael L Klein3, Traci E Clemons4, J Peter Campbell3, Frederick L Ferris5, Emily Y Chew2, Tiarnan D Keenan6. 1. Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada. 2. Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland. 3. Casey Eye Institute, Oregon Health and Science University, Portland, Oregon. 4. Emmes Corporation, Rockville, Maryland. 5. Ophthalmic Research Consultants, LLC, Waxhaw, North Carolina. 6. Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: tiarnan.keenan@nih.gov.
Abstract
PURPOSE: To report the natural history of untreated neovascular age-related macular degeneration (nAMD) regarding subsequent macular atrophy. DESIGN: Prospective cohort within a randomized, controlled trial of oral micronutrient supplements. PARTICIPANTS: Age-Related Eye Disease Study (AREDS) participants (55-80 years) who demonstrated nAMD during follow-up (1992-2005), prior to anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Color fundus photographs were collected at annual study visits and graded centrally for late age-related macular degeneration (AMD). Incident macular atrophy after nAMD was examined by Kaplan-Meier analysis and proportional hazards regression. MAIN OUTCOME MEASURES: Incident macular atrophy after nAMD. RESULTS:Of the 4757 AREDS participants, 708 eyes (627 participants) demonstrated nAMD during follow-up and were eligible. The cumulative risks of incident macular atrophy after untreated nAMD were 9.6% (standard error, 1.2%), 31.4% (standard error, 2.2%), 43.1% (standard error, 2.6%), and 61.5% (standard error, 4.3%) at 2, 5, 7, and 10 years, respectively. This corresponded to a linear risk of 6.5% per year. The cumulative risk of central involvement was 30.4% (standard error, 3.2%), 43.4% (standard error, 3.8%), and 57.0% (standard error, 4.8%) at first appearance of atrophy, 2 years, and 5 years, respectively. Geographic atrophy (GA) in the fellow eye was associated with increased risk of macular atrophy (hazard ratio [HR], 1.70; 95% confidence interval [CI], 1.17-2.49; P = 0.006). However, higher 52-single nucleotide polymorphism AMD genetic risk score was not associated with increased risk of macular atrophy (HR, 1.03; 95% CI, 0.90-1.17; P = 0.67). Similarly, no significant differences were observed according to SNPs at CFH, ARMS2, or C3. CONCLUSIONS: The rate of incident macular atrophy after untreated nAMD is relatively high, increasing linearly over time and affecting half of eyes by 8 years. Hence, factors other than anti-VEGF therapy are involved in atrophy development, including natural progression to GA. Comparison with studies of treated nAMD suggests it may not be necessary to invoke a large effect of anti-VEGF therapy on inciting macular atrophy, although a contribution remains possible. Central involvement is present in one third of eyes at the outset (similar to pure GA) and increases linearly to half at 3 years. Published by Elsevier Inc.
RCT Entities:
PURPOSE: To report the natural history of untreated neovascular age-related macular degeneration (nAMD) regarding subsequent macular atrophy. DESIGN: Prospective cohort within a randomized, controlled trial of oral micronutrient supplements. PARTICIPANTS: Age-Related Eye Disease Study (AREDS) participants (55-80 years) who demonstrated nAMD during follow-up (1992-2005), prior to anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Color fundus photographs were collected at annual study visits and graded centrally for late age-related macular degeneration (AMD). Incident macular atrophy after nAMD was examined by Kaplan-Meier analysis and proportional hazards regression. MAIN OUTCOME MEASURES: Incident macular atrophy after nAMD. RESULTS: Of the 4757 AREDS participants, 708 eyes (627 participants) demonstrated nAMD during follow-up and were eligible. The cumulative risks of incident macular atrophy after untreated nAMD were 9.6% (standard error, 1.2%), 31.4% (standard error, 2.2%), 43.1% (standard error, 2.6%), and 61.5% (standard error, 4.3%) at 2, 5, 7, and 10 years, respectively. This corresponded to a linear risk of 6.5% per year. The cumulative risk of central involvement was 30.4% (standard error, 3.2%), 43.4% (standard error, 3.8%), and 57.0% (standard error, 4.8%) at first appearance of atrophy, 2 years, and 5 years, respectively. Geographic atrophy (GA) in the fellow eye was associated with increased risk of macular atrophy (hazard ratio [HR], 1.70; 95% confidence interval [CI], 1.17-2.49; P = 0.006). However, higher 52-single nucleotide polymorphism AMD genetic risk score was not associated with increased risk of macular atrophy (HR, 1.03; 95% CI, 0.90-1.17; P = 0.67). Similarly, no significant differences were observed according to SNPs at CFH, ARMS2, or C3. CONCLUSIONS: The rate of incident macular atrophy after untreated nAMD is relatively high, increasing linearly over time and affecting half of eyes by 8 years. Hence, factors other than anti-VEGF therapy are involved in atrophy development, including natural progression to GA. Comparison with studies of treated nAMD suggests it may not be necessary to invoke a large effect of anti-VEGF therapy on inciting macular atrophy, although a contribution remains possible. Central involvement is present in one third of eyes at the outset (similar to pure GA) and increases linearly to half at 3 years. Published by Elsevier Inc.
Authors: Tien Y Wong; Tien Wong; Usha Chakravarthy; Ronald Klein; Paul Mitchell; Gergana Zlateva; Ronald Buggage; Kyle Fahrbach; Corey Probst; Isabella Sledge Journal: Ophthalmology Date: 2007-08-06 Impact factor: 12.079
Authors: Robert B Bhisitkul; Thais S Mendes; Soraya Rofagha; Wayne Enanoria; David S Boyer; SriniVas R Sadda; Kang Zhang Journal: Am J Ophthalmol Date: 2015-01-30 Impact factor: 5.258
Authors: Vittorio Capuano; Alexandra Miere; Lea Querques; Riccardo Sacconi; Adriano Carnevali; Francesca Amoroso; Francesco Bandello; Eric H Souied; Giuseppe Querques Journal: Am J Ophthalmol Date: 2017-07-20 Impact factor: 5.258
Authors: Juan E Grunwald; Maxwell Pistilli; Ebenezer Daniel; Gui-Shuang Ying; Wei Pan; Glenn J Jaffe; Cynthia A Toth; Stephanie A Hagstrom; Maureen G Maguire; Daniel F Martin Journal: Ophthalmology Date: 2016-10-27 Impact factor: 12.079
Authors: Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Nathan Congdon; Benita O'Colmain; Caroline C W Klaver; Ronald Klein; Beatriz Muñoz; David S Friedman; John Kempen; Hugh R Taylor; Paul Mitchell Journal: Arch Ophthalmol Date: 2004-04
Authors: Sharon D Solomon; Kristina Lindsley; Satyanarayana S Vedula; Magdalena G Krzystolik; Barbara S Hawkins Journal: Cochrane Database Syst Rev Date: 2014-08-29
Authors: Wan Ling Wong; Xinyi Su; Xiang Li; Chui Ming G Cheung; Ronald Klein; Ching-Yu Cheng; Tien Yin Wong Journal: Lancet Glob Health Date: 2014-01-03 Impact factor: 26.763
Authors: Lars G Fritsche; Wilmar Igl; Jessica N Cooke Bailey; Felix Grassmann; Sebanti Sengupta; Jennifer L Bragg-Gresham; Kathryn P Burdon; Scott J Hebbring; Cindy Wen; Mathias Gorski; Ivana K Kim; David Cho; Donald Zack; Eric Souied; Hendrik P N Scholl; Elisa Bala; Kristine E Lee; David J Hunter; Rebecca J Sardell; Paul Mitchell; Joanna E Merriam; Valentina Cipriani; Joshua D Hoffman; Tina Schick; Yara T E Lechanteur; Robyn H Guymer; Matthew P Johnson; Yingda Jiang; Chloe M Stanton; Gabriëlle H S Buitendijk; Xiaowei Zhan; Alan M Kwong; Alexis Boleda; Matthew Brooks; Linn Gieser; Rinki Ratnapriya; Kari E Branham; Johanna R Foerster; John R Heckenlively; Mohammad I Othman; Brendan J Vote; Helena Hai Liang; Emmanuelle Souzeau; Ian L McAllister; Timothy Isaacs; Janette Hall; Stewart Lake; David A Mackey; Ian J Constable; Jamie E Craig; Terrie E Kitchner; Zhenglin Yang; Zhiguang Su; Hongrong Luo; Daniel Chen; Hong Ouyang; Ken Flagg; Danni Lin; Guanping Mao; Henry Ferreyra; Klaus Stark; Claudia N von Strachwitz; Armin Wolf; Caroline Brandl; Guenther Rudolph; Matthias Olden; Margaux A Morrison; Denise J Morgan; Matthew Schu; Jeeyun Ahn; Giuliana Silvestri; Evangelia E Tsironi; Kyu Hyung Park; Lindsay A Farrer; Anton Orlin; Alexander Brucker; Mingyao Li; Christine A Curcio; Saddek Mohand-Saïd; José-Alain Sahel; Isabelle Audo; Mustapha Benchaboune; Angela J Cree; Christina A Rennie; Srinivas V Goverdhan; Michelle Grunin; Shira Hagbi-Levi; Peter Campochiaro; Nicholas Katsanis; Frank G Holz; Frédéric Blond; Hélène Blanché; Jean-François Deleuze; Robert P Igo; Barbara Truitt; Neal S Peachey; Stacy M Meuer; Chelsea E Myers; Emily L Moore; Ronald Klein; Michael A Hauser; Eric A Postel; Monique D Courtenay; Stephen G Schwartz; Jaclyn L Kovach; William K Scott; Gerald Liew; Ava G Tan; Bamini Gopinath; John C Merriam; R Theodore Smith; Jane C Khan; Humma Shahid; Anthony T Moore; J Allie McGrath; Reneé Laux; Milam A Brantley; Anita Agarwal; Lebriz Ersoy; Albert Caramoy; Thomas Langmann; Nicole T M Saksens; Eiko K de Jong; Carel B Hoyng; Melinda S Cain; Andrea J Richardson; Tammy M Martin; John Blangero; Daniel E Weeks; Bal Dhillon; Cornelia M van Duijn; Kimberly F Doheny; Jane Romm; Caroline C W Klaver; Caroline Hayward; Michael B Gorin; Michael L Klein; Paul N Baird; Anneke I den Hollander; Sascha Fauser; John R W Yates; Rando Allikmets; Jie Jin Wang; Debra A Schaumberg; Barbara E K Klein; Stephanie A Hagstrom; Itay Chowers; Andrew J Lotery; Thierry Léveillard; Kang Zhang; Murray H Brilliant; Alex W Hewitt; Anand Swaroop; Emily Y Chew; Margaret A Pericak-Vance; Margaret DeAngelis; Dwight Stambolian; Jonathan L Haines; Sudha K Iyengar; Bernhard H F Weber; Gonçalo R Abecasis; Iris M Heid Journal: Nat Genet Date: 2015-12-21 Impact factor: 38.330
Authors: Szilárd Kiss; Kristina Oresic Bender; Ruslan N Grishanin; Kelly M Hanna; Julio D Nieves; Pallavi Sharma; Aivan T Nguyen; Romeo J Rosario; Judith S Greengard; Claire M Gelfman; Mehdi Gasmi Journal: Transl Vis Sci Technol Date: 2021-01-29 Impact factor: 3.283
Authors: Maria D Pinazo-Durán; Jose J García-Medina; Silvia M Sanz-González; Jose E O'Connor; Ricardo P Casaroli-Marano; Mar Valero-Velló; Maribel López-Gálvez; Cristina Peris-Martínez; Vicente Zanón-Moreno; Manuel Diaz-Llopis Journal: Diagnostics (Basel) Date: 2021-04-19
Authors: Aniket Ramshekar; Colin A Bretz; Eric Kunz; Thaonhi Cung; Burt T Richards; Gregory J Stoddard; Gregory S Hageman; Brahim Chaqour; M Elizabeth Hartnett Journal: Biomedicines Date: 2022-07-09